Unstoppable Momentum

Tower Cancer Research fuels scientific investigation and clinical impact every day. The work is continuous and not politically influenced or motivated. Because our work is scientific and focused solely on collecting data, accelerating breakthroughs, and, ultimately, saving lives. Right now, Tower Cancer is supporting the work of dozens of researchers, and I want you to know exactly what a few of them are working on today, even as so much federally funded research is paused.

Dr. James Godfrey’s lab is at the frontiers investigating a new class of immunotherapies that activate the immune system to target and kill cancer cells. These bispecific antibodies are approved to treat lymphomas. Dr. Godfrey’s work is likely to be transformative in the field of hematology oncology, and life-changing for those who may be treated with advanced therapies based on his work. Our work at Tower Cancer is to support the creativity and innovative scientific thinking of gifted researchers.

Every year, Tower Cancer’s support extends to several early career grantees whose work we have determined can deliver. Two more I’d like to highlight here: Dr. Jinseok Park’s lab is devoted to understanding how and why the most aggressive forms of childhood soft tissue cancer spread. By examining how cells collaborate, his work aims to stop tumor growth. Dr. Thazin Nwe Aung’s work is made possible by a grant from the Dr. Susan Love Fund at Tower Cancer, in conjunction with the Yale School of Medicine, and extends the pioneering work of Dr. Love by refining mapping of breast tissue and ducts by combining that with genetic data to enhance immunotherapies in patients with triple negative breast cancer.

All three of these doctors exemplify Tower Cancer Research’s core mandate: to support the most promising cancer research and stimulate added funding. What begins in these labs goes on to touch lives. We can’t do it without you.